The Prognostic Impact of Tumor Differentiation on Recurrence and Survival After Resection of Hepatocellular Carcinoma Is Dependent on Tumor Size

Overview

Journal Liver Cancer

Date 2021 Nov 1

PMID 34721508

Citations 25

Authors

Hiroji Shinkawa

Shogo Tanaka

Daijiro Kabata

Shigekazu Takemura

Ryosuke Amano

Kenjiro Kimura

Masahiko Kinoshita

Shoji Kubo

Affiliations

Soon will be listed here.

Abstract

Introduction: The present study aimed to evaluate the effect of poor differentiation and tumor size on survival outcome after hepatic resection of hepatocellular carcinoma (HCC).

Methods: A total of 1,107 patients who underwent initial and curative hepatic resection for HCC without macroscopic vascular invasion participated in the study. Using the multivariable Cox proportional hazards regression model, we evaluated changes in hazard ratios (HRs) for the association between tumor differentiation and survival based on tumor size.

Results: In patients with poorly (Por) differentiated HCCs, the adjusted HRs of reduced overall survival (OS), recurrence-free survival (RFS), early RFS, and early extrahepatic RFS were 1.31 (95% confidence interval [CI]; 1.07-1.59), 1.07 (95% CI 0.89-1.28), 1.31 (95% CI 1.06-1.62), and 1.81 (95% CI 1.03-3.17), respectively. Moreover, based on an analysis of the effect modification of tumor differentiation according to tumor size, Por HCC was found to be associated with a reduced OS ( = 0.033). The HRs of Por HCCs sharply increased in patients with tumors measuring up to 5 cm. The adjusted HRs of reduced OS in patients with Por HCCs measuring <2, ≥2 and <5, and ≥5 cm were 1.22 (95% CI 0.69-2.14), 1.33 (95% CI 1.02-1.73), and 1.58 (95% CI 1.04-2.42), respectively. The corresponding adjusted HRs of reduced early RFS were 0.85 (95% CI 0.46-1.57), 1.34 (95% CI 1.01-1.8), and 1.57 (95% CI 1.03-2.39), respectively. The adjusted HRs of reduced early extrahepatic RFS were 1.89 (95% CI 0.83-4.3) in patients with tumors measuring ≥2 and <5 cm and 2.33 (95% CI 0.98-5.54) in those with tumors measuring ≥5 cm.

Conclusions: Por HCC measuring ≥2 cm was associated with early recurrence. Hence, it had negative effects on OS. After surgery, patients with Por HCC measuring ≥5 cm should be cautiously monitored for early extrahepatic recurrence. These findings will help physicians devise treatment strategies for patients with HCC.

Citing Articles

Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma.

Wu M, Yu H, Pang S, Liu A, Liu J BMC Med Imaging. 2025; 25(1):51.

PMID: 39962429 PMC: 11834502. DOI: 10.1186/s12880-025-01588-2.

Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution.

Wei F, Huang P, Zhang B, Guo R, Yuan Y, Chen J BMC Cancer. 2025; 25(1):159.

PMID: 39875824 PMC: 11773734. DOI: 10.1186/s12885-025-13510-8.

Artificial intelligence-assisted platform performs high detection ability of hepatocellular carcinoma in CT images: an external clinical validation study.

Shan R, Pei C, Fan Q, Liu J, Wang D, Yang S BMC Cancer. 2025; 25(1):154.

PMID: 39871149 PMC: 11773783. DOI: 10.1186/s12885-025-13529-x.

Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival.

Dieu-Merci M, Hu J, Fang X, Zhao R, Xie X, Pan W Transl Cancer Res. 2024; 13(11):5929-5942.

PMID: 39697743 PMC: 11651849. DOI: 10.21037/tcr-24-958.

A new model based on preoperative AFP, albumin, and tumor burden score for predicting microvascular invasion in early-stage HCC.

Chang Y, Tsai M, Tsai C, Wang C, Lin C, Yen Y Am J Cancer Res. 2024; 14(10):4979-4988.

PMID: 39553207 PMC: 11560811. DOI: 10.62347/ZGRJ7827.

References

Takeishi K, Maeda T, Tsujita E, Yamashita Y, Harada N, Itoh S . Predictors of intrahepatic multiple recurrences after curative hepatectomy for hepatocellular carcinoma. Anticancer Res. 2015; 35(5):3061-6. View

. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg. 1989; 19(1):98-129. DOI: 10.1007/BF02471576. View

Taketomi A, Toshima T, Kitagawa D, Motomura T, Takeishi K, Mano Y . Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2010; 17(10):2740-6. DOI: 10.1245/s10434-010-1076-2. View

Hou K, Fu Z, Gong H . Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol. 2015; 21(2):475-83. PMC: 4292278. DOI: 10.3748/wjg.v21.i2.475. View

Lim C, Mise Y, Sakamoto Y, Yamamoto S, Shindoh J, Ishizawa T . Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma. World J Surg. 2014; 38(11):2910-8. DOI: 10.1007/s00268-014-2704-y. View

Kudo M . Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol. 2019; 25(7):789-807. PMC: 6385008. DOI: 10.3748/wjg.v25.i7.789. View

Kluger M, Salceda J, Laurent A, Tayar C, Duvoux C, Decaens T . Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2014; 62(5):1131-40. DOI: 10.1016/j.jhep.2014.12.018. View

Shindoh J, Andreou A, Aloia T, Zimmitti G, Lauwers G, Laurent A . Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2012; 20(4):1223-9. PMC: 3856190. DOI: 10.1245/s10434-012-2739-y. View

Bruix J, Gores G, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. PMC: 4337888. DOI: 10.1136/gutjnl-2013-306627. View

10.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

11.

Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T . Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol. 2005; 40(10):972-9. DOI: 10.1007/s00535-005-1681-1. View

12.

Soylu N . Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. J Gastrointest Cancer. 2020; 51(4):1176-1186. DOI: 10.1007/s12029-020-00499-5. View

13.

Knodell R, Ishak K, Black W, Chen T, Craig R, Kaplowitz N . Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1(5):431-5. DOI: 10.1002/hep.1840010511. View

14.

Wang L, Wang W, Rong W, Li Z, Wu F, Liu Y . Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study. BMC Cancer. 2020; 20(1):614. PMC: 7329435. DOI: 10.1186/s12885-020-07087-7. View

15.

Lee H, Ryu S, Hong S, Seo D, Min H, Jang M . Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. J Gastroenterol Hepatol. 2009; 24(8):1445-50. DOI: 10.1111/j.1440-1746.2009.05965.x. View

16.

Kubo S, Hirohashi K, Tanaka H, Shuto T, Takemura S, Yamamoto T . Usefulness of viral concentration measurement by transcription-mediated amplification and hybridization protection as a prognostic factor for recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2003; 25(1):71-77. DOI: 10.1016/s1386-6346(02)00167-5. View

17.

Tong H, Wei B, Chen S, Xie Y, Zhang M, Zhang L . Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget. 2017; 8(29):48303-48312. PMC: 5564648. DOI: 10.18632/oncotarget.15684. View

18.

Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G . Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status. Liver Cancer. 2018; 7(3):261-276. PMC: 6170901. DOI: 10.1159/000486902. View

19.

Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio G . Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243(2):229-35. PMC: 1448919. DOI: 10.1097/01.sla.0000197706.21803.a1. View

20.

Endo K, Terada T . Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000; 32(1):78-84. DOI: 10.1016/s0168-8278(00)80192-0. View